On June 16th, the 2022 annual shareholders' meeting and board of directors of the company were grandly held at the company's Liuyang production base. Cai Xinya, member of the Party Committee, Vice General Manager, and Chairman of Xingxiang Group, presided over the meeting. Ge Jinwen, Secretary of the Party Committee and President of Hunan Institute of Traditional Chinese Medicine, Liu Baiyan, Vice President of Hunan Institute of Traditional Chinese Medicine, Shen Fanshun, Director and General Manager of the company, as well as representatives of the company's shareholders, directors, and supervisors attended the meeting. Members of the company's management team also attended the meeting as observers.

Before the meeting, the company's shareholder representatives, directors and supervisors visited the company's new production line of formula granules and the newly built exhibition hall, and they fully recognized the progressiveness of the company's intelligent production facilities and equipment, the rationality of the functional layout and the beautification of the plant environment.

The meeting approved proposals such as the "2021 Annual Work Report and Business Work Report for January May 2022", "2021 Annual Financial Settlement Report", "2022 Annual Financial Budget Report", "2021 Annual Profit Distribution", and "14th Five Year Plan" of the company through written and named voting.

Ge Jinwen, Secretary of the Party Committee and President of Hunan Institute of Traditional Chinese Medicine, pointed out at the meeting that the company has achieved remarkable results with the support of various shareholder units. The company's development has a foundation, prospects, challenges, and goals. In the next stage, the company should seize the opportunity of the construction of the national demonstration zone for comprehensive reform of traditional Chinese medicine, scientifically plan and clarify the direction, apply policies, implement projects, and achieve results in place; We must adhere to scientific research and innovation, increase R&D investment and the introduction of key talents, promote the development of new products, and seek long-term stable and sustainable development of the enterprise; The research institute will continue to strengthen cooperation with the company, promote the continuous improvement of the company's business performance and the continuous appreciation of shareholder equity, and jointly contribute to building Hunan into a strong province of traditional Chinese medicine.